

ORIGINAL RESEARCH

Myocardial Involvement in Chagas Disease and Insulin Resistance: A Non-Metabolic Model of Cardiomyopathy

Luis E. Echeverría^{1,2}, Lyda Z. Rojas^{1,3}, Luis A. López³, Oscar L. Rueda-Ochoa⁴, Sergio Alejandro Gómez-Ochoa¹ and Carlos A. Morillo^{5,6}

¹ Public Health and Epidemiological Studies Group, Cardiovascular Foundation of Colombia, Floridablanca, CO

² Heart Failure and Heart Transplant Clinic, Fundación Cardiovascular de Colombia, Floridablanca, Santander, CO

³ Research Group and Development of Nursing Knowledge (GIDCEN-FCV), Research Institute, Cardiovascular Foundation of Colombia, Floridablanca, Santander, CO

⁴ Electrocardiography Research Group, Universidad Industrial de Santander, Bucaramanga, CO

⁵ Department of Cardiac Sciences, Cumming School of Medicine, University of Calgary, Alberta, CA

⁶ Department of Medicine, Cardiology Division, McMaster University, PHRI-HHSC, Hamilton, Ontario, CA

Corresponding author: Dr. Luis E. Echeverría, MD (lusecheverria@fcv.org)

Background: Heart failure (HF) and type 2 Diabetes Mellitus (T2DM) represent two chronic interrelated conditions accounting for significant morbidity and mortality worldwide. Insulin resistance (IR) has been identified as a risk factor for HF; however, the risk of IR that HF confers has not been well elucidated. The present study aims to analyze the association between myocardial involvement in Chronic Chagas Cardiomyopathy (CCM) and IR, taking advantage of this non-metabolic model of the disease.

Methods: Cross-sectional study performed during the period 2015–2016. Adults with a serological diagnosis of Chagas disease were included, being divided into two groups: CCM and non-CCM. IR was determined by HOMA-IR index. Bivariate analysis and multivariate logistic regression were performed to determine the association between IR as an outcome and CCM as primary exposure.

Results: 200 patients were included in the study, with a mean age of 54.7 years and a female predominance (53.5%). Seventy-four (37.0%) patients were found to have IR, with a median HOMA-IR index of 3.9 (Q1 = 3.1; Q3 = 5.1). Multiple metabolic variables were significantly associated with IR. In a model analyzing only individuals with an altered HWI, an evident association between CCM and IR was observed (OR 4.08; 95% CI 1.55–10.73, $p = 0.004$).

Conclusion: CCM was significantly associated with IR in patients with an altered HWI. The presence of this association in a non-metabolic model of HF (in which the myocardial involvement is expected to be mediated mostly by the parasitic infection) may support the evidence of a direct unidirectional correlation between this last and IR.

Keywords: insulin resistance; heart failure; Chagas Disease, type 2 diabetes mellitus

Introduction

Insulin resistance (IR) is recognized as an independent risk factor for heart failure (HF) for more than a century. Multiple epidemiological studies, such as the Framingham Heart Study and the Reykjavik Study, revealed a 2-fold higher risk of incident HF in patients with type 2 Diabetes Mellitus (T2DM) when compared to patients without this risk factor [1–3]. T2DM has also been shown to be a predictor of hospitalization and mortality in the context of HF [4]. However, the possibility of HF causing IR was not considered until recent years, as clinical studies identified a high prevalence of T2DM in HF, which varied from 33% of patients hospitalized with HF in the Euroheart Failure Survey II to 45% in the PARADIGM-HF trial. This prevalence is significantly higher than that observed in the general population (4–7%) [5, 6].

Additionally, prospective studies have found a higher risk of incident Diabetes Mellitus (DM) in individuals with HF, as in the study of The Osservatorio Geriatrico Regione Campania Group, in which DM was developed in 29% of the individuals with HF compared to 18% matched controls [7, 8]. Guglin et al. found a significantly increased risk of a worsening DM status after three or four years after adjusting for multiple confounding variables [9]. This association is supported by multiple pathophysiological mechanisms commonly observed in HF, as the increase in catecholamine levels, which inhibit pancreatic insulin secretion and stimulates hepatic glycogenolysis and gluconeogenesis, and the shift of myocardial metabolic substrate (from fatty acids to glucose) as a result of the low oxygenation state characteristic of HF, which causes a cardiac accumulation of toxic lipids that inhibit insulin signaling [9–11].

Nevertheless, to date, all studies have been performed mostly in ischemic or metabolic heart failure patients, a condition that may influence the association between HF and IR by adding additional risk factors, an effect that may persist even after performing adequate multivariate analyses [8, 9, 11, 12]. Chronic Chagas Cardiomyopathy (CCM) patients usually tend to have less metabolic comorbidities when compared to other non-CCM HF individuals, as was evidenced in the study of Shen et al., which compared the clinical characteristics and outcomes in patients with HF with reduced ejection fraction caused by Chagas disease, with other etiologies, finding a significantly lower prevalence of diabetes mellitus, hypertension and myocardial infarction in CCM patients [13]. Moreover, the pathophysiology of the myocardial involvement in CCM is mainly inflammatory, postulating CCM as a potential unique model to evaluate the effect of HF in determining the risk of IR and DM [14–16]. This study aimed to estimate the prevalence of IR and the incidence of DM (defined as the DM that was unknown for the patients until diagnosed during this study) in Chagas Disease and its association with CCM diagnosis in a non-metabolic model of heart failure.

Methods

Study Design and Population

A cross-sectional study conducted between January 2016 to January 2017 in the Heart Failure and Transplant Clinic of Foundation of Colombia, Floridablanca, Colombia. Patients older than 18 years with positive IgG antibodies for *T. cruzi* by indirect immunofluorescence, ELISA, or haemagglutination test were included. All individuals with diseases associated with cardiometabolic factors relevant to the study such as uncontrolled hypertension, known diabetes mellitus, history of coronary disease or myocardial infarction, valvular disease, Cushing's disease, pheochromocytoma, acromegaly, polycystic ovary and individuals receiving drugs with hypoglycemic effect (except cardioselective beta-blockers) were excluded.

Main Exposure

CCM was considered as the primary exposure. For the assessment of its impact in IR included patients were divided into two groups: the first one comprised individuals with the indeterminate form of the disease (serological diagnosis without any electrocardiographic or echocardiographic abnormality) while the second consisted of patients in which a diagnosis of CCM had been previously established associated with typical echocardiographic (segmental or global wall motion abnormalities, cardiac aneurysms) or electrocardiographic (left anterior fascicular block, left bundle branch block, right bundle branch block, atrioventricular blocks, ventricular premature beats, atrial fibrillation or flutter, bradycardia ≤ 50 beats/min) alterations consistent with CCM regardless of New York Heart Association (NYHA) class.

Outcome Measures

IR was defined as the primary outcome. We chose to use the HOMA-IR index (Homeostasis Model Assessment) to determine IR due to its good correlation with the hyperinsulinemic-euglycemic glucose clamp and its technical advantage of requiring only a single plasma sample assayed for insulin and glucose [17]. The Matthews formula was used to calculate HOMA-IR: $\text{HOMA-IR} = \text{fasting serum insulin (U/l)} \times \text{fasting serum glucose (mg/dl)} / 405$. A patient was considered to have IR if the HOMA-IR index was ≥ 2.5 . Secondary outcomes were conditions derived from IR, such as prediabetes and established DM diagnosis, the diagnosis of these two conditions was performed according to American Diabetes Society criteria: Prediabetes: Fasting blood glucose 100–125 mg/dL or glycated hemoglobin (HbA1c 6.0–6.4%), DM2: Fasting blood glucose ≥ 126 mg/dL or glycated hemoglobin (HbA1c equal or greater than 6.5%).

Confounding Variables

As IR is considered a condition with multifactorial causes, we aimed to analyze all the potential variables that could influence its development. For this purpose, sociodemographic characteristics (age and sex), relevant past medical history (alcohol consumption), anthropometric measures (including hip-waist

index), physical activity (estimated using the International Physical Activity Questionnaires [IPAQ] by a telephonic interview following the World Health Organization recommendations), mean arterial pressure and biological markers, such as total cholesterol and C-reactive protein were measured.

Statistical Analysis

Continuous distributed normal variables are reported as mean \pm SD, non-normally distributed as median with first and third quartiles, and categorical variables are presented as absolute values and percentages. To determine whether there were differences in population sociodemographic and clinical characteristics by insulin resistance, we used Chi-square and Fischer exact test for categorical variables and the unpaired Student t or Mann-Whitney U test for continuous variables.

We examined the association of CCM with insulin resistance (HOMA-IR \geq 2.5 versus $<$ 2.5). We performed a literature search for evaluating the relevant variables to include in the model, along with the ones that could have a potential interaction. We found that in several studies that performed multivariable models considering IR and DM as the outcome measure, hip waist index (HWI) was observed to have a significant p-value for interaction with multiple variables in the models created; therefore, we analyzed HWI as an interaction variable in our analysis [18–20]. Multivariable logistic regression models adjusted by sex, age, mean arterial pressure, alcohol, HWI, group*HWI interaction (p-value = 0.086, considering a significant p-value for interaction as $p < 0.15$), total cholesterol, reactive protein C (CRP) and physical activity, were performed. Given the significant p-value for HWI interaction, we performed a stratified analysis by HWI alteration (Defining a normal HWI as 0.90 or less for men, and 0.80 or less for women). A p-value <0.05 was considered significant. All statistical tests were two-sided. All data were analyzed using Stata Statistical Software, version 14.

The Ethical Review Board of the FCV approved this study. All participants signed an informed consent before their inclusion in the study. This research followed the guidelines stated in the Declaration of Helsinki of the World Medical Association and the Resolution 8430 of 1993 of the Ministry of Health of Colombia.

Results

Two hundred patients were included in the study; the mean age was 54.7 years, with 54% being female. Patients in the CCM group (n = 104; 52%) were significantly older (59 ± 11.1 vs 49 ± 11.4 years) and predominantly male (57.69% vs 34.38%) compared to the CD patients without CCM (n = 96; 48%). The overall prevalence of IR was 37% (n = 74), with a median HOMA-IR index of 3.9 (Q1 = 3.1; Q3 = 5.1); both the continuous value and the proportion of patients with IR (HOMA-IR value $>$ 2.5) were not significantly different in the CCM group compared to the one without CCM (See supplementary Table 1). No significant differences in age, sex, sociodemographic characteristics, left ventricular ejection fraction (LVEF), NT-proBNP and pharmacological treatment were observed when compared to individuals without IR (**Table 1**). Body mass

Table 1: Bivariate Analysis of the Variables Associated with Insulin Resistance in a Population of Patients with Chagas Disease.

Variable	Insulin resistance (Yes) n = 74	Insulin resistance (No) n = 126	p-value
Sex			
Females	46 (62.16)	61 (48.41)	0.060
Males	28 (37.84)	65 (51.59)	
Age (Years)	54.9 ± 10.3	54.4 ± 13.3	0.792
Education			
None	13 (17.57)	10 (7.94)	0.298*
Incomplete Primary School	28 (37.84)	53 (42.06)	
Complete Primary School	18 (24.32)	36 (28.57)	
Incomplete Secondary School	2 (2.70)	5 (3.97)	
Complete Secondary School	8 (10.81)	17 (13.49)	
Technical	1 (1.35)	1 (0.79)	
Incomplete University	0 (0.00)	2 (1.59)	
Complete University	4 (5.41)	2 (1.59)	

(Contd.)

Variable	Insulin resistance (Yes) n = 74	Insulin resistance (No) n = 126	p-value
Occupation			
None	30 (40.54)	49 (38.89)	0.238
Student	0 (0.00)	3 (2.38)	
Employee	9 (12.16)	5 (3.97)	
Independent	28 (37.84)	53 (42.06)	
Unemployed/Dismissed	5 (6.76)	13 (10.32)	
Pensioner/Retired	2 (2.70)	3 (2.38)	
Social Security			
Contributory	25 (33.78)	40 (31.75)	0.677
Subsidized	47 (63.51)	81 (64.29)	
Prepaid	1 (1.35)	0 (0.00)	
Special Regime	1 (1.35)	3 (2.38)	
None	0 (0.00)	2 (1.59)	
Area of Residence			
Urban	47 (63.51)	56 (44.44)	0.009
Rural	27 (36.49)	70 (55.56)	
Smoking			
No	73 (98.65)	122 (96.83)	0.653
Yes	1 (1.35)	4 (3.17)	
Alcohol Consumption			
No	59 (79.73)	90 (71.43)	0.240
Yes	15 (20.27)	36 (28.57)	
Physical Activity			
Low	46 (36.51)	34 (45.95)	0.423*
Moderate	31 (24.60)	19 (25.68)	
High	49 (38.89)	21 (28.38)	
NYHA			
I	62 (83.78)	97 (76.98)	0.252*
II	10 (13.51)	24 (19.05)	
III	2 (2.70)	5 (3.97)	
BMI (kg/m²)	29.5 (25.9–32.3)	24.1 (21.8–26.8)	0.000
HWI	0.93 ± 0.07	0.89 ± 0.08	0.000
SBP (mmHg)	125 ± 17	119 ± 15	0.014
DBP (mmHg)	76 ± 11	71 ± 9.3	0.000
MAP (mmHg)	93 ± 12	87 ± 10	0.000
LVEF (%)	56 (45–60)	58 (43–64)	0.479
Glycaemia (mg/dL)	99 (95–109)	95 (91–101)	0.000
Serum Insulin Levels (mIU/L)	15.3 (12.7–18.9)	6.0 (4.3–7.9)	0.000
Hb1Ac (%)	5.5 (5.2–5.7)	5.4 (5.1–5.6)	0.010
PCR (mg/L)	2.2 (1.3–4.4)	1.2 (0.6–2.8)	0.000
Total Cholesterol (mg/dL)	202 (178–234)	189 (153–215)	0.017
LDL (mg/dL)	122 (96–145)	113 (87–136)	0.140

(Contd.)

Variable	Insulin resistance (Yes) n = 74	Insulin resistance (No) n = 126	p-value
HDL (mg/dL)	38 (33–47)	48 (42–55)	0.000
Triglycerides (mg/dL)	178 (125–279)	110 (83–151)	0.000
NT-proBNP (pg/ml)	101 (42–338)	92 (48–957)	0.236
Aldosterone (pg/mL)	53.5 (36.6–77.5)	58.2 (40.7–94.9)	0.181
Angiotensin-2 (pg/mL)	27.2 (17.5–39.5)	26.2 (16.5–39.1)	0.581
Norepinephrine (pg/mL)	204.1 (95.4–361.1)	233.9 (121.7–404.1)	0.218
HOMA-IR Index	3.9 (3.1–5.1)	1.4 (1.0–1.9)	0.000
ACEI/ARB			
No	41 (55.41)	79 (62.70)	0.370
Yes	33 (44.59)	47 (37.30)	
Beta-blockers			
No	38 (51.35)	77 (61.11)	0.178
Yes	36 (48.65)	49 (38.89)	
Aldosterone Antagonists			
No	55 (74.32)	90 (71.43)	0.658
Yes	19 (25.68)	36 (28.57)	
Diuretics			
No	59 (79.73)	104 (82.54)	0.621
Yes	15 (20.27)	22 (17.46)	
Digoxin			
No	68 (91.89)	119 (94.4)	0.480
Yes	6 (8.11)	7 (5.56)	

This table contains n (%) for categorical variables and median (first and third quartile) or mean (standard deviation) for continuous variables, *Chi2 trend.

Abbreviations: BMI: Body Mass Index; HWI: Hip Waist Index ACEI/ARB: Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker.

index, HWI, systolic, diastolic and mean arterial pressure, C-reactive protein, triglycerides, total cholesterol, and HDL were significantly associated with IR in the bivariate analysis. Interestingly, we found an important prevalence of prediabetes in the studied population (n = 69; 34.5%), also being higher in the group with CCM when compared to those without CCM (37.5% vs. 31.2%; p = 0.235); however, this difference was not statistically significant. Finally, the incidence of DM was 4.02% in the overall population, while it was 1.05% in the CD patients without CCM and 6.73% in those with HF (p = 0.04) (**Figure 1**).

A multivariate logistic regression model was performed to evaluate the association between CCM and IR accounting for potential confounding variables. An imputation process (Imputation through chained equations) was performed in order to optimize the collected information, as some patients had missing information related to IPAQ questionnaires (18.5%). No variation in the results was observed after the imputation was performed. In the first model, which considered a biological interaction of HWI in the studied association, CCM was not associated with IR; however, when analyzing only individuals with an altered HWI, an evident association was observed (OR 4.08; 95% CI 1.55–10.74, p = 0.004) (**Table 2**). This could be explained by the fact that the number of individuals with IR and a normal HWI was low (n = 6; 3%), with most patients with IR in the altered HWI group. Sensitivity analysis was performed to evaluate the impact of the imputation process in the results of the model, and no significant differences were observed comparing both models.

Discussion

In this study, adult individuals with a serological diagnosis of Chagas Disease divided into two groups (with and without CCM) were compared to evaluate the association between CCM and IR in a non-metabolic model of heart failure, finding a significant association in individuals with an altered HWI even when adjust-




Figure 1: Percentages of Newly Diagnosed DM and Pre-diabetes in Individuals with Chagas Disease with and without Chronic Chagas Cardiomyopathy.

Abbreviations: T2DM= Type-2 Diabetes Mellitus; CCM= Chagas cardiomyopathy.

ing by potential confounding variables. This represents a novel finding of a non-metabolic HF model, such as CCM.

The link between IR/DM and HF was considered to be unidirectional, as the evidence available showed that DM was a significant risk factor both for HF development (8% increased risk of HF with each 1% increase in HbA1c) and for a worse prognosis, increasing the risk of HF admissions and death [2, 21]. A bidirectional relationship of this phenomenon has just been recently acknowledged, as epidemiological studies showed a significantly higher prevalence of DM in HF patients. Few studies have addressed the theory of assessing HF as a direct cause of DM [7–9, 12]. Nichols et al., in a cohort of non-diabetic patients, reported that HF of multiple etiologies was independently associated with a 48% increase in the incidence of DM [12]. Amato and colleagues reported in 1,339 elderly subjects that the diagnosis of HF was associated with a 2-fold increase in the development of T2DM development. Untreated HF correlated with a higher prevalence of DM (4.0%, 95 % CI 3.4–5.8); this association was independent of sex, age, and other confounding variables [7]. Similarly, the severity of HF has been correlated with the degree of insulin resistance, with the latter being higher as NYHA class increases and peak VO₂ decreases [22].

The molecular mechanisms underlying this association remain unclear; however, multiple hypotheses have been postulated, highlighting the role of catecholamines, which are typically elevated in HF patients. Such an increase alters cardiac energetic efficiency, favoring lipolysis and elevating the serum levels of free fatty acids, while the increase in sympathetic activity stimulates hepatic gluconeogenesis and glycogenolysis and leads to an inhibited pancreatic insulin secretion, promoting hyperglycemia (**Figure 2**) [10, 11].

HF is characterized by a shift in myocardial metabolism from fatty acids to glucose for ATP production, as obtaining energy from fatty acids requires a higher amount of oxygen available, a condition that is limited under the reduced oxygenation state observed in HF. This shift is relevant because it favors a cardiac accumulation of toxic lipid products, which finally inhibit insulin signaling by reversing the stimulation of protein kinase C activity [23]. Supporting this hypothesis, multiple studies have evaluated the benefit of left ventricular assistance devices (LVAD) in insulin sensitivity in HF patients, favoring an improved blood glucose control after LVAD implantation. Guglin et al. reported a dramatically decreased HbA1C within three months after LVAD implantation that remained at this level for up to 1 year. Similar studies have proved an enhanced myocardial insulin signaling leading to a decrease in insulin resistance, supporting the benefits

Table 2: Statistical Models Evaluating the Association between Heart Failure and Insulin Resistance Considering the Potential Confounders.


Insulin resistance	Model 1			Model 2			Model 3		
	OR	95% CI	p-value	OR	95% CI	p-value	OR	95% CI	p-value
CCM (Yes/No)	0.68	0.11–4.31	0.683	4.08	1.55–10.74	0.004	0.38	0.02–6.81	0.516
Sex (Men vs Women)	0.49	0.24–1.01	0.054	0.56	0.26–1.21	0.142	0.11	0.01–1.57	0.103
Age, years (>60 vs ≤60)	0.18	0.07–0.45	0.000	0.19	0.08–0.49	0.001	1	omitted	
MAP, mmHg (>100 vs ≤100)	2.93	1.21–7.11	0.017	2.83	1.12–7.11	0.027	4.34	0.04–465.2	0.538
Alcohol consumption (Yes/No)	0.55	0.24–1.22	0.142	0.54	0.23–1.26	0.155	0.19	0.01–4.44	0.306
HWI (Yes/No)	2.02	0.47–8.66	0.345	–	–	–	–	–	–
Group*HWI interaction	5.94	0.78–44.96	0.084	–	–	–	–	–	–
Total Cholesterol, mg/dl (>200 vs ≤200)	1.61	0.81–3.23	0.175	1.70	0.80–3.61	0.165	0.77	0.04–14.2	0.861
CRP mg/dl (>3 vs ≤3)	1.85	0.87–3.94	0.109	1.59	0.71–3.61	0.260	9.79	0.52–183.7	0.127
Physical activity (Low)									
Moderate	1.38	0.59–3.19	0.452	1.18	0.48–2.87	0.718	8.99	0.48–167.4	0.141
High	1.06	0.41–2.72	0.909	0.98	0.35–2.73	0.976	0.30	0.01–19.53	0.576

Abbreviations: CCM: Chronic Chagas Cardiomyopathy; MAP: Mean arterial pressure; HWI: Hip Waist Index; CRP: Reactive protein C.

Model 1 = Analysis with HWI interaction.

Model 2 = Including only patients with HWI alteration.

Model 3 = Including only patients without HWI alteration.

**Figure 2:** Pathophysiological Pathways for Insulin Resistance in Heart Failure.

of LVAD in this aspect [24–26]. This benefit may also derive from the resolution of two hemodynamic abnormalities that directly affect the pancreas in HF, namely increased central venous pressure and low cardiac output [27]. Moreover, optimal pharmacological management of HF has known cardioprotective effects and has been shown to alter DM incidence. In the SOLVD and CHARM trials, ACEI/ARB's demonstrated protective effects against the development of DM [28, 29]. However, pharmacological treatment was not associated with IR in the present study.

CCM is characterized by a persistent low-grade *T. cruzi* infection that has marked systemic effects that also involve metabolic pathways related to insulin sensitivity. This association is partly due to the capacity of the parasite of infecting adipose tissue, leading to a significant infiltration of macrophages into adipose tissue and to chronic inflammation, disturbing the metabolic processes that are carried out in this specialized tissue [30, 31]. These processes are mediated mainly by bioactive mediators known as adipocytokines, being adiponectin the most studied one in the Chagas Disease. Clinical studies in CCM have shown reduced levels of insulin in these individuals, mainly due to an increase in adiponectin levels, simultaneous to a decrease in leptin levels, among other alterations that promote a change in the function of the stimulus-secretion pathway [32–34]. Nevertheless, the study of dos Santos et al. reported that among the patients with CD, the individuals with CCM were the only ones with a higher prevalence of T2DM when compared to controls, having the patients with the indeterminate form or the ones with the isolated gastrointestinal form a similar prevalence when compared to healthy volunteers, suggesting that the HF derived from the myocardial involvement of CD may be the primary mechanism of IR in this context [35].

However, even the CCM model is not free of a metabolic influence on IR additional to the HF impact by itself; nevertheless, we aimed to mitigate this effect by including CD patients in both groups and evaluating the age in the multivariate analysis as a proxy of the length the parasite had potentially infected the individual. Moreover, the markers of chronic inflammation (C-reactive protein) and autonomic dysfunction (norepinephrine levels) that could link CD and IR were not statistically different among the two groups, suggesting a more clear and isolated effect of HF diagnosis.

Study Limitations

As a cross-sectional study, we were not able to perform an analysis of causality between the two conditions studied; therefore, we cannot completely rule out the possibility of reverse causation between IR and CCM. Nevertheless, it is widely known that CCM pathophysiology depends mainly on parasite-dependent damage, immune-mediated tissue injury, neurogenic disturbances, and microvascular derangements [15]; besides, only eight patients had a diagnosis of DM2 in our cohort; Meanwhile, 66 patients had a reduced ejection fraction; Therefore, considering that systolic dysfunction represents a late manifestation of diabetic cardiomyopathy occurring mainly in the long term established DM, the probability of myocardial impairment being attributed to DM is low, making unlikely that IR may be the cause of cardiomyopathy in these patients.

Furthermore, the lack of knowledge of the time of infection of the included individuals avoids performing an accurate analysis of this potentially confounding variable; Nevertheless, the age of the participants may serve as a potential proxy of the time of infection, as it usually occurs during childhood, progressing into cardiomyopathy most commonly after 10 to even 30 years. Patients with a longstanding *T. cruzi* infection may have lower insulin sensitivity compared to individuals with a more recent onset of the disease. Moreover, the information regarding physical activity was obtained by phone contact after the initial interview, opening the possibility of potential differences with the IPAQ measurement at this initial contact.

Conclusion

A higher prevalence of IR and DM in this Chagas Disease cohort compared to the epidemiological data of the general population was observed, both in individuals with and without CCM, highlighting the role of *T. cruzi* infection in glucose regulation mechanisms. A significant association was observed between CCM diagnosis and IR; this relation remained significant after adjustment for sex, age, MAP, alcohol consumption, total cholesterol, CRP mg/dl, and physical activity, considering the CCM*HWI interaction. These findings suggest that in a primarily non-metabolic model of disease such as CCM, HF may play a significant role in the development of IR and subsequent progression to DM.

Additional File

The additional file for this article can be found as follows:

- **Supplementary Table 1:** Bivariate Analysis of the Variables Associated with myocardial involvement (CCM) in a Population of Patients with Chagas Disease. DOI: <https://doi.org/10.5334/gh.793.s1>

Abbreviations and Acronyms

BMI = Body mass index
CCM = Chagas cardiomyopathy
CD = Chagas disease
ECG = Electrocardiogram
GLS = Global longitudinal strain
HF = Heart Failure
HWI = Hip waist index
IR = Insulin Resistance
LVEF = Left ventricular ejection fraction
NT-proBNP = NT-terminal pro B-type natriuretic peptide
NYHA = New York Heart Association
CRP = Reactive C Protein
T2DM = Type-2 Diabetes Mellitus

Acknowledgements

The authors thanks patients with Chagas Disease for their participation in this study.

Funding Information

The Colombian government supported LZR and LEE through Departamento Administrativo de Ciencia, Tecnología e Innovación-COLCIENCIAS (project code 656665740365, CT 648-2014); URL: <http://www.colciencias.gov.co/>. The funder had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

Competing Interests

The authors have no competing interests to declare.

Author Contributions

L.E.E.C: Study idea, study design, protocol writing, manuscript critical review
L.Z.R.S: Study design, protocol writing, data analysis, manuscript critical review
L.A.L: Protocol writing, data analysis
O.L.R.O: Study design, manuscript critical review
S.A.G.O: Data analysis, manuscript writing, and review
C.A.M: Study idea, study design, manuscript critical review

References

1. **Leyden E.** Asthma and diabetes mellitus. *Zeitschr Klin Med.* 1881; 3: 358e64.
2. **Kannel WB, Hjortland M, Castelli WP.** Role of diabetes in congestive heart failure: the Framingham study. *Am J Cardiol.* 1974; 34(1): 29–34. DOI: [https://doi.org/10.1016/0002-9149\(74\)90089-7](https://doi.org/10.1016/0002-9149(74)90089-7)
3. **Thrainsdottir IS, Aspelund T, Thorgeirsson G,** et al. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. *Diabetes Care.* 2005; 28(3): 612–6. DOI: <https://doi.org/10.2337/diacare.28.3.612>
4. **MacDonald MR, Petrie MC, Hawkins NM,** et al. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. *Eur Heart J.* 2008; 29(10): 1224–40. DOI: <https://doi.org/10.1093/eurheartj/ehn156>
5. **Nieminen MS, Brutsaert D, Dickstein K,** et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. *Eur Heart J.* 2006; 27(22): 2725–36. DOI: <https://doi.org/10.1093/eurheartj/ehl193>
6. **Adams KF, Fonarow GC, Emerman CL,** et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). *Am Heart J.* 2005; 149(2): 209–16. DOI: <https://doi.org/10.1016/j.ahj.2004.08.005>
7. **Amato L, Paolisso G, Cacciatore F,** et al. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. *Diabetes Metab.* 1997; 23(3): 213–8.

8. **Andersson C, Norgaard ML, Hansen PR**, et al. Heart failure severity, as determined by loop diuretic dosages, predicts the risk of developing diabetes after myocardial infarction: a nationwide cohort study. *Eur J Heart Fail*. 2010; 12(12): 1333–8. DOI: <https://doi.org/10.1093/eurjhf/hfq160>
9. **Guglin M, Lynch K, Krischer J**. Heart Failure as a Risk Factor for Diabetes Mellitus. *Cardiology*. 2014; 129(2): 84–92. DOI: <https://doi.org/10.1159/000363282>
10. **Aroor AR, Mandavia CH, Sowers JR**. Insulin Resistance and Heart Failure: Molecular Mechanisms. *Heart Fail Clin*. 2012; 8(4): 609–17. DOI: <https://doi.org/10.1016/j.hfc.2012.06.005>
11. **Paolisso G, De Riu S, Marrazzo G, Verza M, Varricchio M, D'Onofrio F**. Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. *Metabolism*. 1991; 40(9): 972–7. DOI: [https://doi.org/10.1016/0026-0495\(91\)90075-8](https://doi.org/10.1016/0026-0495(91)90075-8)
12. **Nichols GA, Moler EJ**. Cardiovascular disease, heart failure, chronic kidney disease and depression independently increase the risk of incident diabetes. *Diabetologia*. 2011; 54(3): 523–6. DOI: <https://doi.org/10.1007/s00125-010-1965-8>
13. **Shen L, Ramires F, Martinez F**, et al. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. *Circ Heart Fail*. 2017; 10(11). DOI: <https://doi.org/10.1161/CIRCHEARTFAILURE.117.004361>
14. **Echeverría LE, Morillo CA**. American Trypanosomiasis (Chagas Disease). *Infect Dis Clin*. 1 Mar 2019; 33(1): 119–34. DOI: <https://doi.org/10.1016/j.idc.2018.10.015>
15. **Nunes MCP, Beaton A, Acquatella H**, et al. Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement From the American Heart Association. *Circulation [Internet]*. 18 Sep 2018; 138(12). DOI: <https://doi.org/10.1161/CIR.0000000000000599> (assessed 12 Mar 2019).
16. **Ribeiro AL, Nunes MP, Teixeira MM, Rocha MOC**. Diagnosis and management of Chagas disease and cardiomyopathy. *Nat Rev Cardiol*. 2012; 9(10): 576–89. DOI: <https://doi.org/10.1038/nrcardio.2012.109>
17. **Wallace TM, Levy JC, Matthews DR**. Use and abuse of HOMA modeling. *Diabetes Care*. 2004; 27(6): 1487–95. DOI: <https://doi.org/10.2337/diacare.27.6.1487>
18. **Parker ED, Pereira MA, Stevens J, Folsom AR**. Association of Hip Circumference With Incident Diabetes and Coronary Heart Disease. *Am J Epidemiol*. 2009; 169(7): 837–47. DOI: <https://doi.org/10.1093/aje/kwn395>
19. **Conway B, Xiang Y-B, Villegas R**, et al. Hip Circumference and the Risk of Type 2 Diabetes in Middle-aged and Elderly Men and Women: the Shanghai Women and Shanghai Men's Health Studies. *Ann Epidemiol*. 2011; 21(5): 358–66. DOI: <https://doi.org/10.1016/j.annepidem.2011.02.005>
20. **Liu L, Pang Z, Wang S**, et al. [Synergistic effect of diabetes family history and abnormal waist-to-hip ratio on the incidence of type 2 diabetes]. *Wei Sheng Yan Jiu*. 2012; 41(2): 308–10.
21. **Castagno D, Baird-Gunning J, Jhund PS**, et al. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: Evidence from a 37,229 patient meta-analysis. *Am Heart J*. 2011; 162(5): 938–948.e2. DOI: <https://doi.org/10.1016/j.ahj.2011.07.030>
22. **ALZadjali MA, Godfrey V, Khan F**, et al. Insulin Resistance Is Highly Prevalent and Is Associated With Reduced Exercise Tolerance in Nondiabetic Patients With Heart Failure. *J Am Coll Cardiol*. 2009; 53(9): 747–53. DOI: <https://doi.org/10.1016/j.jacc.2008.08.081>
23. **Guglin M, Villafranca A, Morrison A**. Cardiogenic diabetes. *Heart Fail Rev*. 2014; 19(5): 595–602. DOI: <https://doi.org/10.1007/s10741-013-9412-9>
24. **Guglin M, Maguire K, Missimer T, Faber C, Caldeira C**. Improvement in blood glucose control in patients with diabetes after implantation of left ventricular assist devices. *ASAIO J Am Soc Artif Intern Organs*. 1992. 2014; 60(3): 290–3. DOI: <https://doi.org/10.1097/MAT.0000000000000064>
25. **Koerner MM, El-Banayosy A, Eleuteri K**, et al. Neurohormonal regulation and improvement in blood glucose control: reduction of insulin requirement in patients with a nonpulsatile ventricular assist device. *Heart Surg Forum*. 2014; 17(2): E98–102. DOI: <https://doi.org/10.1532/HSF98.2013323>
26. **Subauste AR, Esfandiari NH, Qu Y**, et al. Impact of left ventricular assist device on diabetes management: an evaluation through case analysis and clinical impact. *Hosp Pract 1995*. 2014; 42(3): 116–22. DOI: <https://doi.org/10.3810/hp.2014.08.1124>
27. **Uriel N, Naka Y, Colombo PC**, et al. Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices. *Eur J Heart Fail*. 2011; 13(2): 195–9. DOI: <https://doi.org/10.1093/eurjhf/hfq204>

28. **Yusuf S, Ostergren JB, Gerstein HC**, et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. *Circulation*. 2005; 112(1): 48–53. DOI: <https://doi.org/10.1161/CIRCULATIONAHA.104.528166>
29. **Vermes E, Ducharme A, Bourassa MG**, et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). *Circulation*. 2003; 107(9): 1291–6. DOI: <https://doi.org/10.1161/01.CIR.0000054611.89228.92>
30. **Tanowitz HB, Jelicks LA, Machado FS**, et al. Adipose Tissue, Diabetes and Chagas Disease. *Adv Parasitol*. 2011; 76: 235–50. DOI: <https://doi.org/10.1016/B978-0-12-385895-5.00010-4>
31. **Cabalén ME, Cabral MF, Sanmarco LM**, et al. Chronic *Trypanosoma cruzi* infection potentiates adipose tissue macrophage polarization toward an anti-inflammatory M2 phenotype and contributes to diabetes progression in a diet-induced obesity model. *Oncotarget*. 2016; 7(12): 13400–15. DOI: <https://doi.org/10.18632/oncotarget.7630>
32. **Barbosa-Ferreira JM, Mady C, Ianni BM**, et al. Dysregulation of Autonomic Nervous System in Chagas' Heart Disease Is Associated with Altered Adipocytokines Levels. *PLoS ONE [Internet]*. 6 Jul 2015; 10(7). DOI: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4493107/> (assessed 1 Apr 2019). DOI: <https://doi.org/10.1371/journal.pone.0131447>
33. **Dabarian AL, Mady C, Barbosa-Ferreira JM**, et al. Dysregulation of insulin levels in Chagas heart disease is associated with altered adipocytokine levels. *Can J Physiol Pharmacol*. 2019; 97(2): 140–5. DOI: <https://doi.org/10.1139/cjpp-2018-0349>
34. **Dufurrena Q, Amjad FM, Scherer PE**, et al. Alterations in pancreatic β cell function and *Trypanosoma cruzi* infection: evidence from human and animal studies. *Parasitol Res*. 2017; 116(3): 827–38. DOI: <https://doi.org/10.1007/s00436-016-5350-5>
35. **dos Santos VM, da Cunha SF, Teixeira Vde P**, et al. Frequency of diabetes mellitus and hyperglycemia in chagasic and non-chagasic women. *Rev Soc Bras Med Trop*. 1999; 32(5): 489–96.

How to cite this article: Echeverría LE, Rojas LZ, López LA, Rueda-Ochoa OL, Gómez-Ochoa SA, Morillo CA. Myocardial Involvement in Chagas Disease and Insulin Resistance: A Non-Metabolic Model of Cardiomyopathy. *Global Heart*. 2020; 15(1): 36. DOI: <https://doi.org/10.5334/gh.793>

Submitted: 08 October 2019

Accepted: 28 February 2020

Published: 24 April 2020

Copyright: © 2020 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See <http://creativecommons.org/licenses/by/4.0/>.



Global Heart is a peer-reviewed open access journal published by Ubiquity Press.

OPEN ACCESS The Open Access logo, featuring the words 'OPEN ACCESS' followed by a lock icon with a diagonal slash through it, indicating that the content is freely available.